The short version of bioavailability fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-26. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Recruitment: This branch carries out Direct Recruitment (out of the 3 possible mechanisms of: 'direct recruitment', 'recruitment by promotion' and 'recruitment by transfer and permanent absorption') by selection to all Group `A’ and certain Group `B’ posts of the services of the Union (including some Union Territories). These recruitments are done either by selection (interview) or through competitive examination. Recruitment Rules: The commission is mandated under Art. 320 of the Constitution of India, read along the UPSC (Exemption from Consultation) Regulations, 1958, to advise on framing and amending of Recruitment and Service Rules for various Group A and Group B posts in the Government of India, and certain autonomous organizations like EPFO, ESIC, DJB, NDMC & Municipal Corporations(s) of Delhi. This Branch carries out this responsibility by facilitating the Ministries / Departments / UT Administrations / Autonomous Organisations in this regard. Services I: Handles disciplinary cases received from various Ministries/Departments and State Governments for the advice of the commission, as required under Article 320 (3)(c). Services II: Handles all other cases that the 'Services I' branch doesn't. It compiles the Annual Report. Also, it coordinates visits of foreign delegations, correspondence with foreign countries, and hosting of international events concerning Public Service Commissions, including the SAARC Member States.
Ring C is formed from the thiamine pyrophosphate (TPP) mediated decarboxylative addition of pyruvate to 2-octenal, catalysed by pigD. PigE then converts the intermediate to an amine (using an amino-acid and PLP) ready for intramolecular condensation. PigB oxidises the resulting ring using oxygen and FAD+, yielding the pyrrole.
Leo Tolstoy's epic novel War and Peace recounts Napoleon's wars between 1805 and 1812 (especially the disastrous 1812 invasion of Russia and subsequent retreat) from a Russian perspective. Stendhal's novel The Charterhouse of Parma opens with a ground-level recounting of the Battle of Waterloo and the subsequent chaotic retreat of French forces. Les Misérables by Victor Hugo takes place against the backdrop of the Napoleonic Wars and subsequent decades, and in its unabridged form contains an epic telling of the Battle of Waterloo. Adieu is a novella by Honoré de Balzac in which can be found a short description of the French retreat from Russia, particularly the battle of Berezina, where the fictional couple of the story are tragically separated. Years later after imprisonment, the husband returns to find his wife still in a state of utter shock and amnesia. He has the battle and their separation reenacted, hoping the memory will heal her state. William Makepeace Thackeray's novel Vanity Fair takes place during the 1815 Napoleonic War – one of its protagonists dies at the Battle of Waterloo. Thackeray states in Chapter XXX "We do not claim to rank among the military novelists. Our place is with the non-combatants. When the decks are cleared for action we go below and wait meekly." And indeed he presents no descriptions of military leaders, strategy, or combat; he describes anxious non-combatants waiting in Brussels for news.
Sources: en.wikipedia.org
=== Nuclear safety and security === Interlocks and safeguards are mandated to minimize this risk. There have been radiation-related accidents, deaths, and injury at such facilities, many of them caused by operators overriding the safety related interlocks. In a radiation processing facility, radiation specific concerns are supervised by special authorities, while "Ordinary" occupational safety regulations are handled much like other businesses. The safety of irradiation facilities is regulated by the United Nations International Atomic Energy Agency and monitored by the different national Nuclear Regulatory Commissions. The regulators enforce a safety culture that mandates that all incidents that occur are documented and thoroughly analyzed to determine the cause and improvement potential. Such incidents are studied by personnel at multiple facilities, and improvements are mandated to retrofit existing facilities and future design. In the US the Nuclear Regulatory Commission (NRC) regulates the safety of the processing facility, and the United States Department of Transportation (DOT) regulates the safe transport of the radioactive sources.
People with early keratoconus often notice a minor blurring or distortion of their vision, as well as an increased sensitivity to light, so they may visit their clinician seeking corrective lenses for reading or driving. At early stages, the symptoms of keratoconus may be no different from those of any other refractive defect of the eye. As the disease progresses, vision deteriorates, sometimes rapidly due to irregular astigmatism. Visual acuity becomes impaired at all distances, and night vision is often poor. Some individuals have vision in one eye that is markedly worse than the other eye. The disease is often bilateral though asymmetrical. Some develop photophobia (sensitivity to bright light), eye strain from squinting in order to read, or itching in the eye, but there is normally little or no sensation of pain. It may cause luminous objects to appear as cylindrical pipes with the same intensity at all points.
===== MeSH D08.811.277.656 – peptide hydrolases (EC 3.4) ===== MeSH D08.811.277.656.149 – atp-dependent proteases MeSH D08.811.277.656.149.200 – endopeptidase clp MeSH D08.811.277.656.149.500 – protease la MeSH D08.811.277.656.300 – endopeptidases MeSH D08.811.277.656.300.066 – aspartic endopeptidases MeSH D08.811.277.656.300.066.180 – cathepsin d MeSH D08.811.277.656.300.066.185 – cathepsin e MeSH D08.811.277.656.300.066.200 – chymosin MeSH D08.811.277.656.300.066.340 – HIV protease MeSH D08.811.277.656.300.066.700 – pepsin a MeSH D08.811.277.656.300.066.780 – renin MeSH D08.811.277.656.300.099 – brinolase MeSH D08.811.277.656.300.133 – cathepsins MeSH D08.811.277.656.300.133.062 – carboxypeptidase c MeSH D08.811.277.656.300.133.125 – cathepsin b MeSH D08.811.277.656.300.133.187 – cathepsin d MeSH D08.811.277.656.300.133.250 – cathepsin e MeSH D08.811.277.656.300.133.375 – dipeptidyl peptidase i MeSH D08.811.277.656.300.174 – coagulase MeSH D08.811.277.656.300.215 – cysteine endopeptidases MeSH D08.811.277.656.300.215.096 – bromelains MeSH D08.811.277.656.300.215.120 – calpain MeSH D08.811.277.656.300.215.126 – caspases MeSH D08.811.277.656.300.215.126.200 – caspase 1 MeSH D08.811.277.656.300.215.133 – cathepsin b MeSH D08.811.277.656.300.215.160 – chymopapain MeSH D08.811.277.656.300.215.350 – ficain MeSH D08.811.277.656.300.215.585 – papain MeSH D08.811.277.656.300.480 – metalloendopeptidases MeSH D08.811.277.656.300.480.205 – collagenases MeSH D08.811.277.656.300.480.205.352 – gelatinase a MeSH D08.811.277.656.300.480.205.360 – gelatinase b MeSH D08.811.277.656.300.480.205.410 – interstitial collagenase MeSH D08.811.277.656.300.480.205.500 – microbial collagenase MeSH D08.811.277.656.300.480.205.615 – neutrophil collagenase MeSH D08.811.277.656.300.480.252 – gelatinases MeSH D08.811.277.656.300.480.252.420 – gelatinase a MeSH D08.811.277.656.300.480.252.445 – gelatinase b MeSH D08.811.277.656.300.480.300 – insulysin MeSH D08.811.277.656.300.480.452 – lysostaphin MeSH D08.811.277.656.300.480.525 – matrix metalloproteinases MeSH D08.811.277.656.300.480.525.352 – gelatinase a MeSH D08.811.277.656.300.480.525.360 – gelatinase b MeSH D08.811.277.656.300.480.525.451 – interstitial collagenase MeSH D08.811.277.656.300.480.525.505 – matrilysin MeSH D08.811.277.656.300.480.525.615 – neutrophil collagenase MeSH D08.811.277.656.300.480.525.810 – stromelysin 1 MeSH D08.811.277.656.300.480.600 – neprilysin MeSH D08.811.277.656.300.480.632 – pregnancy-associated plasma protein-a MeSH D08.811.277.656.300.480.664 – procollagen n-endopeptidase MeSH D08.811.277.656.300.480.680 – pronase MeSH D08.811.277.656.300.480.827 – thermolysin MeSH D08.811.277.656.300.760 – serine endopeptidases MeSH D08.811.277.656.300.760.030 – acrosin MeSH D08.811.277.656.300.760.176 – chymotrypsin MeSH D08.811.277.656.300.760.198 – complement factor b MeSH D08.811.277.656.300.760.200 – complement factor d MeSH D08.811.277.656.300.760.210 – complement factor i MeSH D08.811.277.656.300.760.228 – endopeptidase clp MeSH D08.811.277.656.300.760.247 – endopeptidase k MeSH D08.811.277.656.300.760.284 – enteropeptidase MeSH D08.811.277.656.300.760.300 – factor viia MeSH D08.811.277.656.300.760.310 – factor ixa MeSH D08.811.277.656.300.760.315 – factor xa MeSH D08.811.277.656.300.760.320 – factor xia MeSH D08.811.277.656.300.760.324 – factor xiia MeSH D08.811.277.656.300.760.353 – furin MeSH D08.811.277.656.300.760.442 – kallikreins MeSH D08.811.277.656.300.760.442.700 – plasma kallikrein MeSH D08.811.277.656.300.760.442.725 – prekallikrein MeSH D08.811.277.656.300.760.442.750 – prostate-specific antigen MeSH D08.811.277.656.300.760.442.875 – tissue kallikreins MeSH D08.811.277.656.300.760.501 – mannose-binding protein-associated serine proteases MeSH D08.811.277.656.300.760.560 – pancreatic elastase MeSH D08.811.277.656.300.760.560.500 – leukocyte elastase MeSH D08.811.277.656.300.760.625 – plasmin MeSH D08.811.277.656.300.760.635 – plasminogen activators MeSH D08.811.277.656.300.760.635.075 – anistreplase MeSH D08.811.277.656.300.760.640 – proprotein convertase 1 MeSH D08.811.277.656.300.760.646 – proprotein convertase 2 MeSH D08.811.277.656.300.760.648 – proprotein convertase 5 MeSH D08.811.277.656.300.760.680 – pronase MeSH D08.811.277.656.300.760.733 – protease la MeSH D08.811.277.656.300.760.787 – subtilisins MeSH D08.811.277.656.300.760.787.805 – subtilisin MeSH D08.811.277.656.300.760.855 – thrombin MeSH D08.811.277.656.300.760.875 – tissue plasminogen activator MeSH D08.811.277.656.300.760.895 – trypsin MeSH D08.811.277.656.300.760.910 – urinary plasminogen activator MeSH D08.811.277.656.300.760.955 – venombin a MeSH D08.811.277.656.300.760.955.060 – ancrod MeSH D08.811.277.656.300.760.955.135 – batroxobin MeSH D08.811.277.656.300.775 – streptokinase MeSH D08.811.277.656.300.775.075 – anistreplase MeSH D08.811.277.656.300.775.900 – streptodornase and streptokinase MeSH D08.811.277.656.350 – exopeptidases MeSH D08.811.277.656.350.100 – aminopeptidases MeSH D08.811.277.656.350.100.150 – amino acid naphthylamidases MeSH D08.811.277.656.350.100.150.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.100.160 – antigens, cd13 MeSH D08.811.277.656.350.100.235 – cystinyl aminopeptidase MeSH D08.811.277.656.350.100.373 – glutamyl aminopeptidase MeSH D08.811.277.656.350.100.511 – leucyl aminopeptidase MeSH D08.811.277.656.350.100.511.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.100.755 – pyroglutamyl-peptidase I MeSH D08.811.277.656.350.245 – carboxypeptidases MeSH D08.811.277.656.350.245.055 – carboxypeptidases A MeSH D08.811.277.656.350.245.083 – carboxypeptidase B MeSH D08.811.277.656.350.245.111 – carboxypeptidase C MeSH D08.811.277.656.350.245.167 – carboxypeptidase H MeSH D08.811.277.656.350.245.224 – carboxypeptidase U MeSH D08.811.277.656.350.245.252 – Serine-type D-Ala-D-Ala carboxypeptidase MeSH D08.811.277.656.350.245.280 – gamma-glutamyl hydrolase MeSH D08.811.277.656.350.245.400 – glutamate carboxypeptidase ii MeSH D08.811.277.656.350.245.450 – lysine carboxypeptidase MeSH D08.811.277.656.350.245.500 – muramoylpentapeptide carboxypeptidase MeSH D08.811.277.656.350.297 – dipeptidases MeSH D08.811.277.656.350.350 – dipeptidyl peptidases MeSH D08.811.277.656.350.350.126 – antigens, cd26 MeSH D08.811.277.656.350.350.375 – dipeptidyl peptidase i MeSH D08.811.277.656.350.555 – metalloexopeptidases MeSH D08.811.277.656.350.555.100 – antigens, cd13 MeSH D08.811.277.656.350.555.200 – carboxypeptidase b MeSH D08.811.277.656.350.555.250 – carboxypeptidase h MeSH D08.811.277.656.350.555.300 – carboxypeptidase u MeSH D08.811.277.656.350.555.350 – carboxypeptidases a MeSH D08.811.277.656.350.555.400 – cystinyl aminopeptidase MeSH D08.811.277.656.350.555.500 – glutamate carboxypeptidase ii MeSH D08.811.277.656.350.555.600 – glutamyl aminopeptidase MeSH D08.811.277.656.350.555.700 – leucyl aminopeptidase MeSH D08.811.277.656.350.555.700.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.350.555.750 – lysine carboxypeptidase MeSH D08.811.277.656.350.700 – peptidyl-dipeptidase a MeSH D08.811.277.656.675 – metalloproteases MeSH D08.811.277.656.675.374 – metalloendopeptidases MeSH D08.811.277.656.675.374.102 – adam proteins MeSH D08.811.277.656.675.374.205 – collagenases MeSH D08.811.277.656.675.374.205.352 – gelatinase a MeSH D08.811.277.656.675.374.205.360 – gelatinase b MeSH D08.811.277.656.675.374.205.410 – interstitial collagenase MeSH D08.811.277.656.675.374.205.500 – microbial collagenase MeSH D08.811.277.656.675.374.205.615 – neutrophil collagenase MeSH D08.811.277.656.675.374.252 – gelatinases MeSH D08.811.277.656.675.374.252.420 – gelatinase a MeSH D08.811.277.656.675.374.252.445 – gelatinase b MeSH D08.811.277.656.675.374.300 – insulysin MeSH D08.811.277.656.675.374.452 – lysostaphin MeSH D08.811.277.656.675.374.525 – matrix metalloproteinases MeSH D08.811.277.656.675.374.525.352 – gelatinase a MeSH D08.811.277.656.675.374.525.360 – gelatinase b MeSH D08.811.277.656.675.374.525.451 – interstitial collagenase MeSH D08.811.277.656.675.374.525.505 – matrilysin MeSH D08.811.277.656.675.374.525.615 – neutrophil collagenase MeSH D08.811.277.656.675.374.525.810 – stromelysin 1 MeSH D08.811.277.656.675.374.600 – neprilysin MeSH D08.811.277.656.675.374.632 – pregnancy-associated plasma protein-a MeSH D08.811.277.656.675.374.664 – procollagen n-endopeptidase MeSH D08.811.277.656.675.374.680 – pronase MeSH D08.811.277.656.675.374.827 – thermolysin MeSH D08.811.277.656.675.555 – metalloexopeptidases MeSH D08.811.277.656.675.555.100 – antigens, cd13 MeSH D08.811.277.656.675.555.200 – carboxypeptidase b MeSH D08.811.277.656.675.555.250 – carboxypeptidase h MeSH D08.811.277.656.675.555.300 – carboxypeptidase u MeSH D08.811.277.656.675.555.350 – carboxypeptidases a MeSH D08.811.277.656.675.555.400 – cystinyl aminopeptidase MeSH D08.811.277.656.675.555.500 – glutamate carboxypeptidase ii MeSH D08.811.277.656.675.555.600 – glutamyl aminopeptidase MeSH D08.811.277.656.675.555.700 – leucyl aminopeptidase MeSH D08.811.277.656.675.555.700.400 – leucyl-beta-naphthylamidase MeSH D08.811.277.656.675.555.750 – lysine carboxypeptidase MeSH D08.811.277.656.837 – proprotein convertases MeSH D08.811.277.656.837.124 – carboxypeptidase h MeSH D08.811.277.656.837.186 – carboxypeptidase u MeSH D08.811.277.656.837.249 – furin MeSH D08.811.277.656.837.500 – proprotein convertase 1 MeSH D08.811.277.656.837.562 – proprotein convertase 2 MeSH D08.811.277.656.837.625 – proprotein convertase 5 MeSH D08.811.277.656.837.750 – renin MeSH D08.811.277.656.918 – proteasome endopeptidase complex
=== Sara Dhadwal === Sara Dhadwal (Priyanga Burford) is the president of Pierpoint London in series 1, and oversees its new hire program. Firm and principled, she initially clashes with Gus Sackey when he castigates her for promoting Pierpoint's cutthroat culture, which he blames for the death of his colleague Hari Dhar. However, Sara gradually becomes more in favor of culture change at the company; she views Eric as the primary embodiment of Pierpoint's toxicity, and fires him after Harper reports Eric locking her in a conference room to berate her. She also tries to become a more supportive figure to Gus, but he grows increasingly disillusioned with the firm, and purposely sabotages his interview on reduction-in-force (RIF) day. The same day, Pierpoint's global head of FICC, Bill Adler, offers Harper a chance to retract her complaint against Eric to bring him back to the firm; Sara takes her aside and tries talking her out of it, telling her she has the power to fundamentally change the culture of Pierpoint. Harper, however, rebuffs Sara for seeing her as a victim, and agrees to have Eric rehired.
Sources: en.wikipedia.org
Half-Life was Valve's debut title and the first to use GoldSrc. It received critical acclaim, winning over fifty PC Game of the Year awards. The game was followed up with two expansions, Half-Life: Opposing Force and Half-Life: Blue Shift, both of which ran GoldSrc and were developed by Gearbox Software. Half-Life: Decay, an expansion pack for Half-Life only released on PlayStation 2, was released in 2001 alongside Half-Life's debut on the platform. Unlike other games in the series, it never received an official version for Windows, however an unofficial version of the game was released by independent developers in 2008. Half-Life: Decay was the final iteration in the Half-Life series to run on GoldSrc, with all future entries in the series using the Source and Source 2 engines.
== Receptor action == GnIH binds to the Gαi protein coupled receptor GPR147 to suppress adenylyl cyclase formation of cAMP and inhibit protein kinase cascades affecting gene expression. GnIH inhibits the same signaling pathway that GnRH activates to promote follicle stimulating hormone (FSH) and luteinizing hormone (LH) expression. The compound RF9 is a known GPR147 receptor antagonist.
== Applications and detection methods == FFF is applicable in the sub-micron range (from 1 nm to several microns) in the "normal" mode or up to 50 microns in the so-called steric mode. The transition from normal to steric mode takes place when diffusion becomes negligible at sizes above a micron. FFF is unique in its wide dynamic range of sizes covering both soluble macromolecules and particles or colloids which can be separated in one analysis. Typical applications are high molar mass polymers and polymer composites, nanoparticles, both industrial and environmental, viruses and virus like particles, lipid nanoparticles, extracellular vesicles and other types of biological samples. FFF can be coupled to all types of detectors known, from high-performance liquid chromatography (HPLC) to size-exclusion chromatography (SEC). Due to FFF's similarity to liquid chromatography (LC), a liquid mobile phase passing through the channel, the most common detectors are those that are also used for liquid chromatography. The most frequently used is an ultraviolet-visible spectroscopy (UV-VIS) detector, because of its non-destructive nature. Coupling with multi angle light scattering which allows the calculation of the size of eluting fractions and comparison to values obtained via FFF theory. Another popular detector is inductively coupled plasma mass spectrometry to characterize metallic nanoparticles with high specificity and sensitivity.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.